In FU samples, nine of 27 evaluable patients expressed HER2 and of these, only one patient was clinically diagnosed with HER2+ breast cancer and treated with HER2 targeted therapy (#6, Figure 2A). The gene discussed is ERBB2; the disease is breast carcinoma.